A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 41,104 shares of ANIX stock, worth $129,477. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,104
Previous 41,000 0.25%
Holding current value
$129,477
Previous $91,000 41.76%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$2.21 - $3.48 $229 - $361
104 Added 0.25%
41,104 $129,000
Q1 2024

Apr 24, 2024

BUY
$3.08 - $5.02 $3,080 - $5,020
1,000 Added 2.5%
41,000 $128,000
Q4 2023

Feb 09, 2024

SELL
$2.85 - $4.19 $285 - $419
-100 Reduced 0.25%
40,000 $155,000
Q4 2022

Feb 08, 2023

BUY
$3.78 - $5.81 $94,878 - $145,831
25,100 Added 167.33%
40,100 $170,000
Q3 2022

Oct 17, 2022

BUY
$2.81 - $6.15 $42,150 - $92,250
15,000 New
15,000 $0

Others Institutions Holding ANIX

About Anixa Biosciences Inc


  • Ticker ANIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,661,700
  • Market Cap $96.6M
  • Description
  • Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...
More about ANIX
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.